Topical Dermatologic Corticosteroids: In Vivo Bioequivalence; Draft Guidance for Industry; Availability | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

Open for Comments

FDA-2022-D-2170

Topical Dermatologic Corticosteroids: In Vivo Bioequivalence; Draft Guidance for Industry; Availability

Documents

Comments

Description

OPEN

Comment Period OpensOct 24, 2022

Comment Period ClosesDec 24, 2022

Type	Title	Posted	Comments	Status
Other	Topical Dermatologic Corticosteroids: In Vivo Bioequivalence; Guidance for Industry; Final Guidance	Jul 14, 2026	--

Total Comments

OGD

CDER

Topical Dermatologic Corticosteroids

In Vivo Bioequivalence;

Draft Guidance for Industry; Availability

OPEN